We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Feds Rip PhRMA's Free Speech Claims In FCA Off-Label Suit

Law360, New York (August 29, 2014, 5:26 PM EDT) -- The U.S. Department of Justice is urging a California federal judge to reject free speech arguments advanced in a False Claims Act case by Pharmaceutical Research and Manufacturers of America, adding more fuel to a fiery debate surrounding punishment of off-label promotion.

In a strongly worded brief Thursday, the DOJ tore into a recent amicus brief that PhRMA filed in a case accusing Schering-Plough Corp. — now part of Merck & Co. — and Millennium Pharmaceuticals Inc. of promoting the blood clot drug Integrilin for unapproved...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.